U.S. Biopharmaceutical Third-party Logistics Market To Reach $87.44 Billion By 2030

U.S. Biopharmaceutical Third-party Logistics Market Growth & Trends

The U.S. biopharmaceutical third-party logistics market size is estimated to reach USD 87.44 billion by 2030, registering to grow at a CAGR of 7.56% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.

The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.

The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.

 Request a free sample copy or view report summary: U.S. Biopharmaceutical Third-party Logistics Market Report

U.S. Biopharmaceutical Third-party Logistics Market Highlights

• The non-cold chain logistics segment accounted for the largest revenue share of 58.39% in 2024. The segment is primarily driven by the distribution of standard biopharmaceutical products that do not require stringent temperature control, allowing for a broader range of transportation and storage options.

• The warehousing and storage segment dominated the market in 2024. This segment provides specialized storage solutions for both temperature-sensitive and non-sensitive products, integrating high-tech systems such as automated warehouses and real-time inventory management.

• The specialty drugs segment accounted for the largest revenue share in the market in 2024 and is expected to witness the highest CAGR over the estimated timeline. This is attributed to the unique handling requirements of these high-value, often temperature-sensitive medications.

U.S. Biopharmaceutical Third-party Logistics Market Segmentation

Grand View Research has segmented the U.S. biopharmaceutical third-party logistics market based on supply chain, service, and product:

U.S. Biopharmaceutical Third-party Logistics Supply Chain Outlook (Revenue, USD Billion, 2018 - 2030)

• Cold Chain

• Non-cold Chain

U.S. Biopharmaceutical Third-party Logistics Service Outlook (Revenue, USD Billion, 2018 - 2030)

• Transportation

• Air Freight

• Sea Freight

• Overland

• Warehousing & Storage

• Other Services

U.S. Biopharmaceutical Third-party Logistics Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Specialty Drugs

• Generics

• Plasma Derived Products

• Others

List of Key Players in U.S. Biopharmaceutical Third-party Logistics Market

• UPS Healthcare

• Cardinal Health

• KUEHNE + NAGEL

• AmerisourceBergen Corp.

• McKesson Corporation

• Thermo Fisher Scientific

• DHL International GmbH

• DB Schenker

• Kerry Logistics Network Ltd.

• CEVA Logistics

• Agility Logistics

• SF Express

• XPO Logistics

• Cencora, Inc.

• EVERSANA